Highlights Newsletter 1
This newsletter presents you the following key sessions:
2. Sugemalimab safe and effective as consolidation for patients with unresectable stage III NSCLC
3. Sotorasib in combination with pembrolizumab or atezolizumab in advanced KRASG12C NSCLC
5. First-line pembrolizumab plus platinum-etoposide for extensive-stage small-cell lung cancer